May 28 (Reuters) - Amgen Inc:
* Prolia(R) (denosumab) granted marketing authorization in the European union
* Says Prolia is under regulatory review in the United States, Switzerland,
Australia and Canada
* Says Prolia reduced the risk of fractures in treatment of postmenopausal
osteoporosis in women
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Prolia(R) (denosumab) granted marketing authorization in the European union
* Says Prolia is under regulatory review in the United States, Switzerland,
Australia and Canada
* Says Prolia reduced the risk of fractures in treatment of postmenopausal
osteoporosis in women
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
